<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rmt</journal-id><journal-title-group><journal-title xml:lang="ru">Общая реаниматология</journal-title><trans-title-group xml:lang="en"><trans-title>General Reanimatology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1813-9779</issn><issn pub-type="epub">2411-7110</issn><publisher><publisher-name>FSBI "SRIGR" RAMS</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15360/1813-9779-2025-2-2541</article-id><article-id custom-type="elpub" pub-id-type="custom">rmt-2541</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Биохимические предикторы исхода при печеночной недостаточности на фоне синдрома механической желтухи</article-title><trans-title-group xml:lang="en"><trans-title>Biochemical Predictors of Clinical Outcome in Liver Failure Associated with Obstructive Jaundice</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2150-3662</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мамошина</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Mamoshina</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мамошина Ирина Валерьевна.</p><p>302028, Орловская область, Орел, Бульвар Победы, д. 10</p></bio><bio xml:lang="en"><p>Irina V. Mamoshina.</p><p>10 Pobedy Boulevard, Oryol, 302028 Oryol Region</p></bio><email xlink:type="simple">mamoshinai@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4272-0957</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Петрова</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Petrova</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Петрова Марина Владимировна.</p><p>107031, Москва, ул. Петровка, д. 25, стр. 2; 117198, Москва, ул. Миклухо-Маклая, д. 6</p></bio><bio xml:lang="en"><p>Marina V. Petrova.</p><p>25 Petrovka Str., Bldg. 2, 107031 Moscow; 6 Miklukho-Maсlaya Str., 117198 Moscow</p></bio><email xlink:type="simple">mail@petrovamv.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1787-5156</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мамошин</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Mamoshin</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мамошин Андриан Валерьевич.</p><p>115093, Москва, ул. Большая Серпуховская, д. 27</p></bio><bio xml:lang="en"><p>Andrian V. Mamoshin.</p><p>27 Bolshaya Serpukhovskaya Str., 115093 Moscow</p></bio><email xlink:type="simple">dr.mamoshin@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Орловская областная клиническая больница</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Oryol Regional Clinical Hospital</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Федеральный научно-клинический центр реаниматологии и реабилитологии; Медицинский институт Российского университета дружбы народов им. Патриса Лумумбы</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology; Medical Institute, Patrice Lumumba Peoples Friendship University of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр хирургии им. А.В. Вишневского Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>A.V. Vishnevsky National Medical Research Center for Surgery, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>23</day><month>04</month><year>2025</year></pub-date><volume>21</volume><issue>2</issue><fpage>16</fpage><lpage>24</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Мамошина И.В., Петрова М.В., Мамошин А.В., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Мамошина И.В., Петрова М.В., Мамошин А.В.</copyright-holder><copyright-holder xml:lang="en">Mamoshina I.V., Petrova M.V., Mamoshin A.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.reanimatology.com/rmt/article/view/2541">https://www.reanimatology.com/rmt/article/view/2541</self-uri><abstract><p>Актуальность изучения предикторов неблагоприятного исхода печеночной недостаточности обусловлена стремительным увеличением числа пациентов c механической желтухой (МЖ) и отсутствием унифицированных диагностических критериев оценки функционального состояния печени. Цель исследования. Изучить динамику показателей биомаркеров повреждения печени при печеночной недостаточности на фоне МЖ.</p><sec><title>Материал и методы</title><p>Материал и методы. Провели обсервационное проспективное когортное исследование биологических маркеров повреждения печени (белок L-FABP, 5-нуклеотидаза, аргиназа печени, гиалуроновая кислота) в сыворотке крови пациентов с печеночной недостаточностью на фоне МЖ доброкачественного генеза. В исследование включили 53 пациента после выполнения декомпрессии желчевыводящих путей. По динамике течения патологического процесса пациентов разделили на две группы: с благоприятным (1-я группа, n=27) и неблагоприятным исходом (2-я группа, n=26). Группу сравнения представили 25 здоровыми донорами. Содержание биомаркеров в сыворотке крови оценивали в день поступления, на 3-и, 7-е и 11-е сут после декомпрессионного вмешательства. Исследование выполняли методом иммуноферментного анализа. Для статистической обработки эмпирических данных использовали пакет программ IBM SPSS Statistics 22. Статистический анализ включал двухфакторный анализ Фридмана, H-критерий Краскела−Уоллеса, U-критерий Манна−Уитни, двухвыборочный критерий Колмогорова-Смирнова. Статистически значимые результаты учитывали при р&lt;0,05.</p></sec><sec><title>Результаты</title><p>Результаты. При госпитализации медианные значения исследуемых биомаркеров в обеих группах были заметно выше, чем в группе сравнения. В группе 1 наблюдали статистически значимое снижение концентрации всех биомаркеров в процессе лечения (р=0,01 — белок L-FABP, 5-нуклеотидаза, аргиназа печени; р=0,03 — гиалуроновая кислота). В группе 2 значимо снижалась только концентрация белка L-FABP (р=0,04). Чувствительность и специфичность в прогнозировании исхода заболевания для L−FABP составили 89,2–92,3% и 88,9–96,3%, для 5-нуклеотидазы — 53,8−69,2% и 81,5−85,2%, для аргиназы — 57,7−76,9% и 77,8−88,9%, для гиалуроновой кислоты — 38,5−46,2% и 74,1−81,5% соответственно.</p></sec><sec><title>Заключение</title><p>Заключение. Среди исследованных биологических маркеров наиболее высокой специфичностью и чувствительностью в отношении исхода при печеночной недостаточности на фоне МЖ обладает белок L-FABP, другие биомаркеры продемонстрировали менее значимые результаты.</p></sec></abstract><trans-abstract xml:lang="en"><p>The study of predictors of adverse outcomes in liver failure is driven by the rapid increase in patients with obstructive jaundice (OJ) and the lack of standardized diagnostic criteria for assessing liver functional status.</p><sec><title>Aim</title><p>Aim. To investigate the changes of liver injury biomarkers in liver failure associated with OJ.</p></sec><sec><title>Materials and Methods</title><p>Materials and Methods. A prospective observational cohort study was conducted on serum biomarkers of liver injury — L-FABP protein, 5'-nucleotidase, liver arginase, and hyaluronic acid — in patients with liver failure due to benign OJ. The study included 53 patients who underwent biliary decompression. Based on the course of disease, patients were divided into two groups: those with favorable outcomes (group 1, N=27) and those with unfavorable outcomes (group 2, N=26). A control group consisted of 25 healthy donors. Serum biomarker levels were assessed on admission and on days 3, 7 and 11 post-decompression. The study used enzyme-linked immunosorbent assay (ELISA). Statistical analysis was performed using IBM SPSS Statistics 22, including Friedman two-way analysis, Kruskal–Wallis H test, Mann–Whitney U test, and two-sample Kolmogorov–Smirnov test, with significance set at P&lt;0.05.</p></sec><sec><title>Results</title><p>Results. At hospital admission, median biomarker levels were significantly higher in both patient groups than in the comparison group. Group 1 showed a statistically significant decrease in all biomarkers during treatment (P=0.01 for L-FABP, 5'-nucleotidase, liver arginase; P=0.03 for hyaluronic acid). In group 2, only L-FABP levels decreased significantly (P=0.04). Sensitivity and specificity for predicting disease outcome were 89.2–92.3% and 88.9–96.3% for L-FABP, 53.8–69.2% and 81.5–85.2% for 5'-nucleotidase, 57.7–76.9% and 77.8–88.9% for arginase, and 38.5–46.2% and 74.1–81.5% for hyaluronic acid, respectively.</p></sec><sec><title>Conclusion</title><p>Conclusion. Among the studied biomarkers, L-FABP showed the highest specificity and sensitivity values for prediction of outcome in liver failure associated with OJ, while other biomarkers demonstrated less significant results.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>механическая желтуха</kwd><kwd>печеночная недостаточность</kwd><kwd>биомаркеры повреждения печени</kwd><kwd>L-FABP</kwd><kwd>5-нуклеотидаза</kwd><kwd>аргиназа печени</kwd><kwd>гиалуроновая кислота</kwd></kwd-group><kwd-group xml:lang="en"><kwd>obstructive jaundice</kwd><kwd>liver failure</kwd><kwd>biomarkers of liver injury</kwd><kwd>L-FABP</kwd><kwd>5'-nucleotidase</kwd><kwd>liver arginase</kwd><kwd>hyaluronic acid</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Кабанов М. Ю., Семенцов К. В., Бояринов Д. Ю., Мянзелин М. Н., Беликова М. Я., Алексеев В. В. Трудности оценки тяжести дисфункции печени при механической желтухе. Анналы хирургической гепатологии. 2021; 26 (2): 129–136. DOI: 10.16931/10.16931/1995-5464.2021-2-129-136.</mixed-citation><mixed-citation xml:lang="en">Kabanov M. Yu., Sementsov K. V., Boyarinov D. Yu., Myanzelin M. N., Belikova M. Ya., Alekseev V. V. Difficulties in assessing the severity of liver dysfunction for obstructive jaundice. Annals of HPB Surgery = Annaly Khirurgicheskoy Gepatologii. 2021; 26 (2): 129–136. (In Russ.). DOI: 10.16931/1995-5464.2021-2-129-136.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Винник Ю. С., Пахомова Р. А., Кочетова Л. В., Воронова Е. А., Козлов В. В., Кириченко А. К. Предикторы печеночной недостаточности при механической желтухе. Хирургия. Журнал им. Н. И. Пирогова. 2018; (3): 37–41. DOI: 10.17116/hirurgia2018337-41.</mixed-citation><mixed-citation xml:lang="en">Vinnik Yu. S., Pakhomova R. A., Kochetova L. V., Voronova E. A., Kozlov V. V., Kirichenko A. K. Predictors of hepatic insufficiency in obstructive jaundice. Pirogov Russian Journal of Surgery = Khirurgiya. Zurnal im. N. I. Pirogova. 2018; (3): 37–41. (In Russ.). DOI: 10.17116/hirurgia2018337-41.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Fernández J., Bassegoda O., Toapanta D., Bernal W. Acute liver failure: a practical update. JHEP reports. 2024; 6 (9): 101131. DOI: 10.1016/j.jhepr.2024.101131. PMID: 39170946.</mixed-citation><mixed-citation xml:lang="en">Fernández J., Bassegoda O., Toapanta D., Bernal W. Acute liver failure: a practical update. JHEP reports. 2024; 6 (9): 101131. DOI: 10.1016/j.jhepr.2024.101131. PMID: 39170946.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Liu J-.J., Sun Y.-M., Xu Y., Mei H.-W., Guo W., Li Z.-L. Pathophysiological consequences and treatment strategy of obstructive jaundice. World J Gastrointest Surg. 2023; 15 (7): 1262–1276. DOI: 10.4240/wjgs.v15.i7.1262. PMID: 37555128.</mixed-citation><mixed-citation xml:lang="en">Liu J-.J., Sun Y.-M., Xu Y., Mei H.-W., Guo W., Li Z.-L. Pathophysiological consequences and treatment strategy of obstructive jaundice. World J Gastrointest Surg. 2023; 15 (7): 1262–1276. DOI: 10.4240/wjgs.v15.i7.1262. PMID: 37555128.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Sha J., Dong Y., Niu H. A prospective study of risk factors for in-hospital mortality in patients with malignant obstructive jaundice undergoing percutaneous biliary drainage. Medicine (Baltimore). 2019; 98 (15): e15131. DOI: 10.1097/MD.0000000000015131. PMID: 30985679.</mixed-citation><mixed-citation xml:lang="en">Sha J., Dong Y., Niu H. A prospective study of risk factors for in-hospital mortality in patients with malignant obstructive jaundice undergoing percutaneous biliary drainage. Medicine (Baltimore). 2019; 98 (15): e15131. DOI: 10.1097/MD.0000000000015131. PMID: 30985679.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Tamber S. S., Bansal P., Sharma S., Singh R. B., Sharma R. Biomarkers of liver diseases. Mol Biol Rep. 2023; 50 (9): 7815–7823. DOI: 10.1007/s11033-023-08666-0. PMID: 37482588.</mixed-citation><mixed-citation xml:lang="en">Tamber S. S., Bansal P., Sharma S., Singh R. B., Sharma R. Biomarkers of liver diseases. Mol Biol Rep. 2023; 50 (9): 7815–7823. DOI: 10.1007/s11033-023-08666-0. PMID: 37482588.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Mangia A. Biomarkers use and development in hepatology: insights on the latest applications. Cells. 2022; 12 (1): 104. DOI: 10.3390/cells12010104. PMID: 36611898.</mixed-citation><mixed-citation xml:lang="en">Mangia A. Biomarkers use and development in hepatology: insights on the latest applications. Cells. 2022; 12 (1): 104. DOI: 10.3390/cells12010104. PMID: 36611898.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Петрова М. В., Мамошина И. В. Прогнозирование неблагоприятного исхода у больных с печеночной недостаточностью на фоне синдрома механической желтухи: проспективное наблюдательное исследование. Вестник интенсивной терапии им. А. И. Салтанова. 2024; 2: 83–93. DOI: 10.21320/1818-474X-2024-2-83-93.</mixed-citation><mixed-citation xml:lang="en">Petrova M. V., Mamoshina I. V. Predicting an unfavorable outcome in patients with liver failure associated with obstructive jaundice syndrome: a prospective observational study. Ann Crit Care = Vestnik Intensivnoy Terapii im AI Saltanova. 2024; 2: 83–93. (In Russ). DOI: 10.21320/1818-474X-2024-2-83-93.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Liang Y., Guo G. L., Zhang L. Current and emerging molecular markers of liver diseases: a pathogenic perspective. Gene expr. 2022; 21 (1): 9–19. DOI: 10.14218/GEJLR.2022.00010. PMID: 38911667.</mixed-citation><mixed-citation xml:lang="en">Liang Y., Guo G. L., Zhang L. Current and emerging molecular markers of liver diseases: a pathogenic perspective. Gene expr. 2022; 21 (1): 9–19. DOI: 10.14218/GEJLR.2022.00010. PMID: 38911667.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Власов А. П., Шейранов Н. С., Маркин О. В., Власова Т. И., Муратова Т. А., Рязанцев В. Е., Тимошкин Д. Е., с соавт. Способ оценки тяжести механической желтухи неопухолевого генеза. Журнал им. Н. В. Склифосовского «Неотложная медицинская помощь». 2021; 10 (1): 174–180. DOI: 10.23934/2223-9022-2021-10-1-174-180.</mixed-citation><mixed-citation xml:lang="en">Vlasov A. P., Sheyranov N. S., Markin O. V., Vlasova T. I., Muratova T. A., Ryazantsev V. E., Timoshkin D. E., et al. A method for assessing the severity of obstructive jaundice of non-neoplastic origin. Russian Sklifosovsky Journal «Emergency Medical Care» = Zhurnal im. N. V. Sklifosovskogo «Neotlozhnaya Meditsinskaya Pomoshch». 2021; 10 (1): 174–180. (In Russ.) DOI: 10.23934/2223-9022-2021-10-1-174-180.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Рузибойзода К. Р., Гулов М. К., Сафарзода А. М., Сафаров Б. И., Халимов Дж.С., Гуломов Л. А., Нуров З. Х. Оптимизация лечения печеночной недостаточности у больных механической желтухой. Вестник НМХЦ им. Н. И. Пирогова. 2023; 18 (3): 66–70. DOI: 10.25881/20728255_2023_18_3_66.</mixed-citation><mixed-citation xml:lang="en">Ruziboyzoda K. R., Gulov M. K., Safarzoda A. M., Safarov B. I., Khalimov J. S., Gulomov L. A., Nurov Z. Kh. Optimization of the treatment of liver failure in patients with obstructive jaundice. Bulletin of Pirogov National Medical &amp; Surgical Center = Vestnik NMCKh im. N. I. Pirogova. 2023; 18 (3): 66–70. (In Russ.). DOI: 10.25881/20728255_2023_18_3_66.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Семенцов К. В., Бояринов Д. Ю., Мянзелин М. Н., Кошелев Т. Е. Современные подходы к оценке влияния механической желтухи на функциональное состояние печени. Вестник НМХЦ им. Н. И. Пирогова. 2024; 19 (1): 110–114. DOI: 10.25881/20728255_2023_19_1_110.</mixed-citation><mixed-citation xml:lang="en">Sementsov K. V., Boyarinov D. Yu., Myanzelin M. N., Koshelev T. E. Modern approaches to the assessment of the impact of mechanical jaundice on the functional state of the liver. Bulletin of Pirogov National Medical &amp; Surgical Center = Vestnik NMCKh im. N. I. Pirogova. 2024; 19 (1): 110–114. (In Russ.). DOI: 10.25881/20728255_2023_19_1_110.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Eguchi A., Iwasa M. The role of elevated liver-type fatty acid-binding proteins in liver diseases. Pharm Res. 2021; 38 (1): 89–95. DOI: 10.1007/s11095-021-02998-x. PMID: 33534129.</mixed-citation><mixed-citation xml:lang="en">Eguchi A., Iwasa M. The role of elevated liver-type fatty acid-binding proteins in liver diseases. Pharm Res. 2021; 38 (1): 89–95. DOI: 10.1007/s11095-021-02998-x. PMID: 33534129.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Abdulaziz B. A., Abdu S. A., Amin A. M., El Menyawi A. K. A. H., Ahmed A., Khalil M. A., Halim W. A. A. Assessment of liver fatty acid binding protein (L-FABP) as a diagnostic marker in non-alcoholic fatty liver disease. Open Journal of Gastroenterology. 2019; 9: 113–124. DOI: 10.4236/ojgas.2019.96014.</mixed-citation><mixed-citation xml:lang="en">Abdulaziz B. A., Abdu S. A., Amin A. M., El Menyawi A. K. A. H., Ahmed A., Khalil M. A., Halim W. A. A. Assessment of liver fatty acid binding protein (L-FABP) as a diagnostic marker in non-alcoholic fatty liver disease. Open Journal of Gastroenterology. 2019; 9: 113–124. DOI: 10.4236/ojgas.2019.96014.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Gökçen P., Çakmak E., Adali G., Doğan H. O., Yildiz S., Ozturk O., Doğanay H. L., et al. Liver fatty acid binding protein: is it an early diagnostic and prognostic marker in liver damage? Medical Science and Discovery. 2021; 8 (4): 213–218. DOI: 10.36472/msd.v8i4.516.</mixed-citation><mixed-citation xml:lang="en">Gökçen P., Çakmak E., Adali G., Doğan H. O., Yildiz S., Ozturk O., Doğanay H. L., et al. Liver fatty acid binding protein: is it an early diagnostic and prognostic marker in liver damage? Medical Science and Discovery. 2021; 8 (4): 213–218. DOI: 10.36472/msd.v8i4.516.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Камышников В. С. Клинико-лабораторная диагностика заболеваний печени. 3-е изд. М.: МЕДпресс-информ; 2019.</mixed-citation><mixed-citation xml:lang="en">Kamyshnikov V. S. Clinical and laboratory diagnostics of liver diseases. 3 d ed. M.: MEDpress-inform; 2019. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Elmes M. W., Prentis L. E., McGoldrick L.L., Giuliano C. J., Sweeney J. M., Joseph O. M., Che J., et al. FABP1 controls hepatic transport and biotransformation of Δ9-THC. Sci Rep. 2019; 9 (1): 7588. DOI: 10.1038/s41598-019-44108-3. PMID: 31110286.</mixed-citation><mixed-citation xml:lang="en">Elmes M. W., Prentis L. E., McGoldrick L.L., Giuliano C. J., Sweeney J. M., Joseph O. M., Che J., et al. FABP1 controls hepatic transport and biotransformation of ?9-THC. Sci Rep. 2019; 9 (1): 7588. DOI: 10.1038/s41598-019-44108-3. PMID: 31110286.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Buechler C., Aslanidis C. Role of lipids in pathophysiology, diagnosis and therapy of hepatocellular carcinoma. Biochim Biophys Acta Mol Cell Biol Lipids. 2020; 1865 (5): 158658. DOI: 10.1016/j.bbalip.2020.158658. PMID: 32058031.</mixed-citation><mixed-citation xml:lang="en">Buechler C., Aslanidis C. Role of lipids in pathophysiology, diagnosis and therapy of hepatocellular carcinoma. Biochim Biophys Acta Mol Cell Biol Lipids. 2020; 1865 (5): 158658. DOI: 10.1016/j.bbalip.2020.158658. PMID: 32058031.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Kulkarni A. V., Sharma M., Kumar P., Simhadri V., Sowmya T. R., Mitnala S., Reddy D. N., et al. Adipocyte fatty acid-binding protein as a predictor of outcome in alcohol-induced acute-on-chronic liver failure. J Clin Exp Hepatol. 2021; 11 (2): 201–208. DOI: 10.1016/j.jceh.2020.07.010. PMID: 33746445.</mixed-citation><mixed-citation xml:lang="en">Kulkarni A. V., Sharma M., Kumar P., Simhadri V., Sowmya T. R., Mitnala S., Reddy D. N., et al. Adipocyte fatty acid-binding protein as a predictor of outcome in alcohol-induced acute-on-chronic liver failure. J Clin Exp Hepatol. 2021; 11 (2): 201–208. DOI: 10.1016/j.jceh.2020.07.010. PMID: 33746445.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Aimaitijiang M., Wu T.-T., Zheng Y-.Y., Hou X.-G., Yang H., Yang Y., Xie X. Serum 5‘-nucleotidase as a novel predictor of adverse clinical outcomes after percutaneous coronary intervention in patients with coronary artery disease. Rev Cardiovasc Med. 2024; 25 (1): 17. DOI: 10.31083/j.rcm2501017. PMID: 39077643.</mixed-citation><mixed-citation xml:lang="en">Aimaitijiang M., Wu T.-T., Zheng Y-.Y., Hou X.-G., Yang H., Yang Y., Xie X. Serum 5‘-nucleotidase as a novel predictor of adverse clinical outcomes after percutaneous coronary intervention in patients with coronary artery disease. Rev Cardiovasc Med. 2024; 25 (1): 17. DOI: 10.31083/j.rcm2501017. PMID: 39077643.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Habib S., Shaikh O. S. Approach to jaundice and abnormal liver function test results. In book: Zakim and Boyer’s Hepatology. 7th ed: Elsevier; 2018: 99–116. DOI: 10.1016/B978-0-323-37591-7.00007-0.</mixed-citation><mixed-citation xml:lang="en">Habib S., Shaikh O. S. Approach to jaundice and abnormal liver function test results. In book: Zakim and Boyer’s Hepatology. 7 th ed: Elsevier; 2018: 99–116. DOI: 10.1016/B978-0-323-37591-7.00007-0.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Кишкун А. А. Руководство по лабораторным методам диагностики. М.: ГЭОТАР-Медиа; 2014.</mixed-citation><mixed-citation xml:lang="en">Kishkun A. A. Manual of laboratory diagnostic methods. Moscow: GEOTAR-Media; 2014. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Xue X.-M., Liu Y.-Y., Chen X.-M., Tao B.-Y., Liu P., Zhou H.-W., Zhang C., et al. Pan-cancer analysis identifies NT5E as a novel prognostic biomarker on cancer-associated fibroblasts associated with unique tumor microenvironment. Front Pharmacol. 2022; 13: 1064032. DOI: 10.3389/fphar.2022.1064032. PMID: 36569293.</mixed-citation><mixed-citation xml:lang="en">Xue X.-M., Liu Y.-Y., Chen X.-M., Tao B.-Y., Liu P., Zhou H.-W., Zhang C., et al. Pan-cancer analysis identifies NT5E as a novel prognostic biomarker on cancer-associated fibroblasts associated with unique tumor microenvironment. Front Pharmacol. 2022; 13: 1064032. DOI: 10.3389/fphar.2022.1064032. PMID: 36569293.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Галеева Н. В. Активность фермента 5`-нуклеотидазы у больных хроническим гепатитом С с обострением естественного течения болезни и его терапевтическая коррекция. Практическая Медицина. 2020; 18 (4): 97–102.</mixed-citation><mixed-citation xml:lang="en">Galeeva N. V. Activity level of 5`-nucleotidase enzyme in patients with chronic hepatitis C with an exacerbation of the disease natural course and its therapeutic correction. Practical Medicine = Prakticheskaya Meditsina. 2020; 18 (4): 97–102. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Li M., Qin J., Xiong K., Jiang B., Zhang T. Review of arginase as a promising biocatalyst: characteristics, preparation, applications and future challenges. Crit Rev Biotechnol. 2022; 42 (5): 651–667. DOI: 10.1080/07388551.2021.1947962. PMID: 34612104.</mixed-citation><mixed-citation xml:lang="en">Li M., Qin J., Xiong K., Jiang B., Zhang T. Review of arginase as a promising biocatalyst: characteristics, preparation, applications and future challenges. Crit Rev Biotechnol. 2022; 42 (5): 651–667. DOI: 10.1080/07388551.2021.1947962. PMID: 34612104.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Kaneko J. J., Harvey J. W., Bruss M. L. Clinical biochemistry of domestic animals. 6th ed: Academic Press; 2008. DOI: 10.1016/B978-012396305-5/50032-4.</mixed-citation><mixed-citation xml:lang="en">Kaneko J. J., Harvey J. W., Bruss M. L. Clinical biochemistry of domestic animals. 6 th ed: Academic Press; 2008. DOI: 10.1016/B978-012396305-5/50032-4.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Al-Khateeb R., Prpic J. Hyaluronic acid: the reason for its variety of physiological and biochemical functional properties. Applied Clinical Research, Clinical Trials and Regulatory Affairs. 2019; 6 (2): 112–159. DOI: 10.2174/2213476X06666190405094637.</mixed-citation><mixed-citation xml:lang="en">Al-Khateeb R., Prpic J. Hyaluronic acid: the reason for its variety of physiological and biochemical functional properties. Applied Clinical Research, Clinical Trials and Regulatory Affairs. 2019; 6 (2): 112–159. DOI: 10.2174/2213476X06666190405094637.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Younesi S., Parsian H. Diagnostic accuracy of glycoproteins in the assessment of liver fibrosis: a comparison between laminin, fibronectin, and hyaluronic acid. Turk J Gastroenterol. 2019; 30 (6): 524–531. DOI: 10.5152/tjg.2019.17339. PMID: 31144658.</mixed-citation><mixed-citation xml:lang="en">Younesi S., Parsian H. Diagnostic accuracy of glycoproteins in the assessment of liver fibrosis: a comparison between laminin, fibronectin, and hyaluronic acid. Turk J Gastroenterol. 2019; 30 (6): 524–531. DOI: 10.5152/tjg.2019.17339. PMID: 31144658.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Chen Z., Ma Y., Cai J., Sun M., Zeng L., Wu F., Zhang Y., et al. Serum biomarkers for liver fibrosis. Clin Chim Acta. 2022; 537: 16–25. DOI: 10.1016/j.cca.2022.09.022. PMID: 36174721.</mixed-citation><mixed-citation xml:lang="en">Chen Z., Ma Y., Cai J., Sun M., Zeng L., Wu F., Zhang Y., et al. Serum biomarkers for liver fibrosis. Clin Chim Acta. 2022; 537: 16–25. DOI: 10.1016/j.cca.2022.09.022. PMID: 36174721.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Matsumoto T., Aoki T., Shimizu T., Park K. H., Shiraki T., Sakuraoka Y., Mori S., Iso Y., et al. Prognostic significance of preoperative hyaluronic acid level in patients with hepatocellular carcinoma. HPB: (Oxford). 2022; 24 (4): 525–534. DOI: 10.1016/j.hpb.2021.09.001. PMID: 34654620.</mixed-citation><mixed-citation xml:lang="en">Matsumoto T., Aoki T., Shimizu T., Park K. H., Shiraki T., Sakuraoka Y., Mori S., Iso Y., et al. Prognostic significance of preoperative hyaluronic acid level in patients with hepatocellular carcinoma. HPB: (Oxford). 2022; 24 (4): 525–534. DOI: 10.1016/j.hpb.2021.09.001. PMID: 34654620.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
